Healthcare provider profile · identity verified

Timothy Daniel Reagan, NP

Nurse Practitioner · CARSON CITY, NV · NPI 1841292869

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	425	40
Amlodipine Besylate	Amlodipine Besylate	219	42
Gabapentin	Gabapentin	212	50
Atorvastatin Calcium	Atorvastatin Calcium	205	39
Eliquis	Apixaban	197	18
Sertraline Hcl	Sertraline Hcl	185	28
Metformin Hcl	Metformin Hcl	179	28
Lisinopril	Lisinopril	175	43
Furosemide	Furosemide	172	24
Trazodone Hcl	Trazodone Hcl	157	29
Divalproex Sodium	Divalproex Sodium	129	25
Hydroxyzine Hcl	Hydroxyzine Hcl	124	36
Quetiapine Fumarate	Quetiapine Fumarate	106	23
Carvedilol	Carvedilol	105	23
Pantoprazole Sodium	Pantoprazole Sodium	102	23
Buspirone Hcl	Buspirone Hcl	89	17
Risperidone	Risperidone	84	15
Mirtazapine	Mirtazapine	83	19
Potassium Chloride	Potassium Chloride	81	16
Tamsulosin Hcl	Tamsulosin Hcl	81	15
Baclofen	Baclofen	76	suppressed
Olanzapine	Olanzapine	69	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	67	13
Ondansetron Hcl	Ondansetron Hcl	66	22
Duloxetine Hcl	Duloxetine Hcl	65	13
Metoprolol Tartrate	Metoprolol Tartrate	59	19
Xarelto	Rivaroxaban	53	suppressed
Cephalexin	Cephalexin	50	33
Oxybutynin Chloride	Oxybutynin Chloride	50	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	50	suppressed
Losartan Potassium	Losartan Potassium	49	20
Tramadol Hcl	Tramadol Hcl	46	21
Methocarbamol	Methocarbamol	45	13
Jardiance	Empagliflozin	43	suppressed
Oxycodone Hcl	Oxycodone Hcl	43	18
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Levetiracetam	Levetiracetam	41	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Clopidogrel	Clopidogrel Bisulfate	38	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	36	suppressed
Meloxicam	Meloxicam	35	suppressed
Carbamazepine	Carbamazepine	34	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	33	suppressed
Memantine Hcl	Memantine Hcl	33	suppressed
Methenamine Hippurate	Methenamine Hippurate	31	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	31	suppressed
Finasteride	Finasteride	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	suppressed
Lorazepam	Lorazepam	29	suppressed
Bupropion Hcl Sr	Bupropion Hcl	28	suppressed
Midodrine Hcl	Midodrine Hcl	28	suppressed
Gemtesa	Vibegron	27	suppressed
Metoprolol Succinate	Metoprolol Succinate	27	11
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Digoxin	Digoxin	25	suppressed
Simvastatin	Simvastatin	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Spiriva Handihaler	Tiotropium Bromide	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Amoxicillin	Amoxicillin	22	13
Benztropine Mesylate	Benztropine Mesylate	22	suppressed
Glipizide	Glipizide	22	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Primidone	Primidone	22	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	21	16
Spironolactone	Spironolactone	21	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Prednisone	Prednisone	19	13
Albuterol Sulfate Hfa	Albuterol Sulfate	18	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Cholestyramine Light	Cholestyramine	17	suppressed
Doxepin Hcl	Doxepin Hcl	17	suppressed
Prazosin Hcl	Prazosin Hcl	17	suppressed
Rytary	Carbidopa/Levodopa	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	13
Tiotropium Bromide	Tiotropium Bromide	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Abilify Maintena	Aripiprazole	16	suppressed
Bupropion Hcl	Bupropion Hcl	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Temazepam	Temazepam	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Cefdinir	Cefdinir	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	13
Famotidine	Famotidine	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	14	suppressed
Humalog	Insulin Lispro	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Vraylar	Cariprazine Hcl	13	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Klayesta	Nystatin	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Lacosamide	Lacosamide	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Perseris	Risperidone	11	suppressed
Polymyxin B Sul-Trimethoprim	Polymyxin B Sulf/Trimethoprim	11	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	11	suppressed
Xcopri	Cenobamate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error